Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins Market Domination Hosts Julie ...

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...

Two supercharged income stocks -- sporting yields of 5.6% and 5.8% -- have the tools and intangibles needed to catapult ...

As we move further into October, many investors may be looking to identify certain stocks with the potential to provide ...

You can find plenty of affordable stocks that offer solid long-term growth prospects. If you're interested in the healthcare ...

In a previous interview, Lee hinted that a period of market volatility is expected, as 2024 heads for a soft landing.

Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...

Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...

Pfizer (NYSE: PFE) stock jumped 3.1% through 11:20 a.m. ET Monday morning in response to a Wall Street Journal article over ...

Here are some of the major companies whose stocks moved on the week’s news.

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00. The ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price ...